Strategies to Optimize Pain Management With Opioids While Minimizing Risk of Abuse

PM and R

Volumn 2, Issue 6, 2010, Pages 544-558

  Brennan, Michael J ^a   Stanos, Steven ^b  

^a The Pain Center of Fairfield   (United States)

^b REHABILITATION INSTITUTE OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUROX; ALO 01; COL 003; ELI 216; EXALGO; HYDROMORPHONE; ILLICIT DRUG; LYSERGIDE; MORPHINE; MORPHINE SULFATE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NICOTINIC ACID; OXYCODONE; OXYNAL; PHENCYCLIDINE; PTI 821; REXISTA; TQ 1015; TQ 1017; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIA; CHRONIC PAIN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; OPIATE ADDICTION; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; SCREENING TEST;

ALGORITHMS; ANALGESICS, OPIOID; CHRONIC DISEASE; HUMANS; PAIN; REFERRAL AND CONSULTATION; RISK FACTORS; RISK MANAGEMENT; SUBSTANCE-RELATED DISORDERS;

EID: 77954601357     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2010.03.011     Document Type: Review

References (119)

1. Gallagher R.M., and Rosenthal L.J. Chronic pain and opiates: Balancing pain control and risks in long-term opioid treatment. Arch Phys Med Rehabil 89 (2008) S77-S82
2. Katz W.A., and Barkin R.L. Dilemmas in chronic/persistent pain management. Am J Ther 15 (2008) 256-264
3. Portenoy R., Ugarte C., Fuller I., and Haas G. Population-based survey of pain in the United States: Differences among white, African American, and Hispanic subjects. J Pain 5 (2004) 317-328
4. Trescot A.M., Boswell M.V., Atluri S.L., Hansen H.C., Deer T.R., Abdi S., et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 9 (2006) 1-39
5. Trescot A.M., Helm S., Hansen H., Benyamin R., Glaser S.E., Adlaka R., et al. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP Guidelines). Pain Physician 11 (2008) S5-S62
6. Katz N.P., Adams E.H., Chilcoat H., Colucci R.D., Comer S.D., Goliber P., et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 23 (2007) 648-660
7. Gagnon A.M., Kahan M., and Srivastava A. Opioid use and abuse: Is there a problem?. Clin J Pain 23 (2007) 661-662
8. Kuehn B.M. Opioid prescriptions soar: Increase in legitimate use as well as abuse. JAMA 297 (2007) 249-251
9. US Department of Health and Human Services. Identification of Drug and Biological Products Deemed to Have Risk Evaluation and Mitigation Strategies for Purposes of the Food and Drug Administration Amendments Act of 2007. Docket No. FDA-2008-N0174. Federal Register 73 (2008) 16313-16314
10. Chronic Pain in America: Roadblocks to Relief; a study conducted by Roper Starch Worldwide for American Academy of Pain Medicine, American Pain Society and Janssen Pharmaceutica (January 1999)
11. Katz N.P., Adams E.H., Benneyan J.C., Birnbaum H.G., Budman S.H., Buzzeo R.W., et al. Foundations of opioid risk management. Clin J Pain 23 (2007) 103-118
12. McCarberg B., and Stanos S. Key patient assessment tools and treatment strategies for pain management. Pain Pract 8 (2008) 423-432
13. McCarberg B.H., Nicholson B.D., Todd K.H., Palmer T., and Penles L. The impact of pain on quality of life and the unmet needs of pain management: Results from pain sufferers and physicians participating in an Internet survey. Am J Ther 15 (2008) 312-320
14. Hariharan J., Lamb G.C., and Neuner J.M. Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med 22 (2007) 485-490
15. Stanos S. Use of opioids. J Fam Pract 56 (2007) 23-32
16. Sloan P., and Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 3 (2006) 489-497
17. Wilson J.F. Strategies to stop abuse of prescribed opioid drugs. Ann Intern Med 146 (2007) 897-900
18. Nwokeji E.D., Rascati K.L., Brwon C.M., and Eisenberg A. Influences of attitudes on family physicians' willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain. Clin Ther 29 (2007) 2589-2602
19. IMS NPA Rx Monthly. IMS Health Web site. http://www.imshealth.com Accessed September 23, 2009
20. Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2008). Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Rockville, MD.
21. Birnbaum H.G., White A.G., Reynolds J.L., Greenberg P.E., Zhang M., Vallow S., et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal perspective. Clin J Pain 22 (2006) 667-676
22. Johnston L.D., O'Malley P.M., Bachman J.G., and Schulenberg J.E. Various stimulant drugs show continuing gradual declines among teens in 2008, most illicit drugs hold steady (December 11, 2008), University of Michigan News Service, Ann Arbor, M.I. http://monitoringthefuture.org/pressreleases/08drugpr.pdf Accessed September 23, 2009
23. Inciardi J.A., Surratt H.L.K.S.P., and Cicero T.J. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 8 (2007) 171-183
24. Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2007). Results from the 2006 National Survey on Drug Use and Health: National Findings (NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD.
25. Denisco R.A., Chandler R.K., and Compton W.M. Addressing the intersecting problems of opioid misuse and chronic pain treatment. Exp Clin Psychopharmacol 16 (2008) 417-428
26. Inciardi J.A., Surratt H.L., Cicero T.J., and Beard R.A. Prescription opioid abuse and diversion in an urban community: The results of an ultrarapid assessment. Pain Med 10 (2009) 537-548
27. Gourlay D.L., and Heit H.A. Pain and addiction: Managing risk through comprehensive care. J Addictive Dis 27 (2008) 23-30
28. Passik S. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psychopharmacol 16 (2008) 400-404
29. Harden R.N. Chronic pain and opiates: A call for moderation. Arch Phys Med Rehabil 89 (2008) S72-S76
30. Fleming M.F., Balousek S.L., Klessig C.L., Mundt M.P., and Brown D.D. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 8 (2007) 573-582
31. Ives T.J., Chelminski P.R., Hammett-Stabler C.A., Malone R.M., Perhac J.S., Potisek N.M., et al. Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Serv Res 6 (2006) 46
32. Cicero T.J., Surratt H., Inciardi J.A., and Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 16 (2007) 827-840
33. Martell B.A., O'Connor P.G., Kerns R.D., Becker W.C., Morales K.H., Kosten T.R., et al. Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction. Ann Intern Med 146 (2007) 116-127
34. Manchikanti L., and Singh A. Therapeutic opioids: A ten year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 11 (2008) S63-S88
35. Fishbain D.A., Cole B., Lewis J., Rosomoff H.L., and Rosomoff R.S. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors?. A structured evidence-based review. Pain Med 9 (2008) 444-459
36. Rosenblum A., Marsch L.A., and Joseph H. Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Exp Clin Psychopharmacol 16 (2008) 405-416
37. Rosenblum A., Joseph H., Fong C., Kipnis S., Cleland C., and Portenoy R.K. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 289 (2003) 2370-2378
38. Savage S.R. Assessment for addiction in pain-treatment settings. Clin J Pain 18 (2002) S28-S38
39. McLellan A.T., and Turner B. Prescription opioids, overdose deaths, and physician responsibility. JAMA 300 (2008) 2672-2673
40. Under the counter: the diversion and abuse of controlled prescription drugs in the US. The National Center on Addiction and Substance Abuse at Columbia University (July 2005). http://www.casacolumbia.org/absolutenm/articlefiles/380-Under%20the%20Co unter%20-%20Diversion.pdf Accessed September 24, 2009
41. Blake S., Ruel B., Seamark C., and Seamark D. Experiences of patients requiring strong opioid drugs for chronic non-cancer pain: A patient-initiated study. Br J Gen Pract 57 (2007) 101-108
42. White A.G., Birnbaum H.G., Mareva M.N., Daher M., Vallow S., Schein J., et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 11 (2005) 469-479
43. Manchikanti L. Prescription drug abuse: What is being done to address this new drug epidemic?. Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician 9 (2006) 287-321
44. Dunn K.M., Saunders K.W., Rutter C.M., Banta-Green C.J., Merrill J.O., Sullivan M.D., et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med 152 (2010) 85-92
45. Chou R., Fanciullo G.J., Fine P.G., Adler J.A., Ballantyne J.C., Davies P., et al. Opioid treatment guidelines. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10 (2009) 113-130
46. Højsted J., and Sjogren P. Addiction to opioids in chronic pain patients: A literature review. Eur J Pain 11 (2007) 490-518
47. Webster L.R., and Webster R.M. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med 6 (2005) 432-442
48. Brown R.L., and Rounds L.A. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J 94 (1995) 135-140
49. Coambs R.B., Larry J.L., Santhiapillai A.C., Abrahamsohn R.V., and Atance C.M. The SISAP: A new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain wihtin general medical practice. Pain Res Manage 1 (1996) 155-162
50. Passik S.D., Kirsh K.L., McDonald M.V., Ahn S.S., Russak S.M., Martin L., et al. A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients. J Pain Symptom Manage 19 (2000) 274-286
51. Cowan D.T., Wilson-Barnett J., Griffiths P., and Allan L.G. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med 4 (2003) 340-351
52. Friedman R., Li V., and Mehrotra D. Treating pain patients at risk: Evaluation of a screening tool in opioid-treated pain patients with and without addiction. Pain Med 4 (2003) 182-185
53. Butler S.F., Budman S.H., Fernandez K., and Jamison R.N. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 112 (2004) 65-75
54. Akbik H., Butler S.F., Budman S.H., Fernandez K., Katz N.P., and Jamison R.N. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage 32 (2006) 287-293
55. Adams L.L., Gatchel R.J., Robinson R.C., Polatin P., Gajraj N., Deschner M., et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage 27 (2004) 440-459
56. Holmes C.P., Gatchel R.J., Adams L.L., Stowell A.W., Hatten A., Noe C., et al. An opioid screening instrument: Long-term evaluation of the utility of the pain medication questionnaire. Pain Pract 6 (2006) 74-88
57. Butler S.F., Budman S.H., Fernandez K.C., Houle B., Benoit C., Katz N., et al. Development and validation of the current opioid misuse measure. Pain 130 (2007) 144-156
58. Butler S.F., Fernandez K., Benoit C., Budman S.H., and Jamison R.N. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 9 (2008) 360-372
59. Compton P.A., Wu S.M., Schieffer B., and Pham Q.N.B.D. Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement compliance. J Pain Symptom Manage 336 (2008) 383-395
60. Compton P., Darakjian J., and Miotto K. Screening for addiction in patients with chronic pain and "problematic" substance use: Evaluation of a pilot assessment tool. J Pain Symptom Manage 16 (1998) 355-363
61. Chabal C., Erjavec M.K., Jacobson L., Mariano A., and Chaney E. Prescription opiate abuse in chronic pain patients: Clinical criteria, incidence, and predictors. Clin J Pain 13 (1997) 150-155
62. Manchikanti L., Atluri S., Trescot A.M., and Giordano J. Monitoring opioid adherence in chronic pain patients: Tools, techniques, and utility. Pain Physician 11 (2008) S155-S180
63. Michna E., Ross E.L., Hynes W.L., Nedeljkovic S.S., Soumekh S., Janfaza D., et al. Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. J Pain Symptom Manage 28 (2004) 250-258
64. Turk D.C., Swanson K.S., and Garchel R.J. Predicting opioid misuse by chronic pain patients. A systematic review and literature synthesis. Clin J Pain 24 (2008) 497-508
65. Passik S.D., Kirsh K.L., Whitcomb L., Portenoy R.K., Katz N.P., Kleinman L., et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 26 (2004) 552-561
66. Passik S.D., and Kirsh K.L. Screening for opioid abuse potential. Pain 16 (2008) 1-4
67. Wu S.M., Compton P., Bolus R., Schieffer B., Pham Q., Baria A., et al. The addiction behaviors checklist: Validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage 32 (2006) 342-351
68. Belgrade M.J., Schamber C.D., and Lindgren B.R. The DIRE score: Predicting outcomes of opioid prescribing for chronic pain. J Pain 7 (2006) 671-681
69. Skinner H.A. The drug abuse screening test. Addict Behav 7 (1982) 363-371
70. Benyamin R., Trescot A.M., Datta S., Buenmaventura R., Adlaka R., Sehgal N., et al. Opioid complications and side effects. Pain Physician 11 (2008) S105-S120
71. Washington State Agency Medical Directors' Group. Interagency Guideline on Opioid dosing for chronic non-cancer pain: An educational pilot to improve care and safety with opioid treatment. Agency Medical Directors Group. March 2007. http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf Accessed September 24, 2009
72. Atluri S.L., and Sudarshan G. Development of a screening tool to detect the risk of inappropriate prescription opioid use in patients with chronic pain. Pain Physician 7 (2004) 333-338
73. Gourlay D.L., Heit H.A., and Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 6 (2005) 107-112
74. Nafziger A.N., and Bertino J.S. Utility and applications of urine drug testing in chronic pain management with opioids. Clin J Pain 25 (2009) 73-79
75. Reisfield G.M., Salazar E., and Bertholf R.L. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 37 (2007) 301-314
76. Compton P. The role of urine toxicology in chronic opioid analgesic therapy. Pain Manage Nurs 8 (2007) 166-172
77. Wasan A.D., Michna E., Janafsca D., Greenfield S., Teter C.J., and Jamison R.N. Interpreting urine drug tests: Prevalence of morphine metabolism to hydromoprhone in chronic pain patients treated with morphine. Pain Med 9 (2008) 918-923
78. Thompson A.R. The importance of opioid tolerance: a therapeutic paradox. J Am Coll Surg 196 (2003) 321-324
79. Collett B.J. Opioid tolerance: The clinical perspective. Br J Anaesth 81 (1998) 58-68
80. Chou R., Ballantyne J.C., Fanciullo G.J., Fine P.G., and Miaskovski C. Research gaps on use of opioids for chronic noncancer pain: Findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline. J Pain 10 (2009) 147-159
81. Ballantyne J.C., and Shin N.S. Efficacy of opioids for chronic pain. Clin J Pain 24 (2008) 469-478
82. Noble M., Tregear S.J., Treadwell J.R., and Schoelles K. Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 35 (2008) 214-228
83. Portenoy R.K., Farrar J.T., Backonja M.M., Cleeland C.S., Yang K., Friedman M., et al. Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study. Clin J Pain 23 (2007) 287-299
84. Soin A., Cheng J., Brown L., Moufawad S., and Mekhail N. Functional outcomes in patients with chronic nonmalignant pain on long-term opioid therapy. Pain Pract 8 (2008) 379-384
85. Devulder J., Richarz U., and Nataraja S.H. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin 21 (2005) 1555-1568
86. Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 10 (2007) 399-424
87. Gilson A.M., Joranson D.E., Maurer M.A., Ryan K.M., and Garthwaite J.P. Progress to achieve balanced state policy relevant to pain management and palliative care. J Pain Palliat Care Pharmacother 19 (2005) 13-26
88. Wiedemer N.L., Harden P.S., Arndt I.O., and Gallagher R.M. The opioid renewal clinic: A primary care, managed approach to opiod therapy in chronic pain patients at risk for substance abuse. Pain Med 8 (2007) 573-584
89. Harris J.M., Elliott T.E., Davis B.E., Chabal C., Fulgineti J.V., and Fine P.G. Educating generalist physicians about chronic pain: Live experts and online education can providedurable benefits. Pain Med 9 (2008) 555-563
90. Simoni-Wastila L., and Tompkins C. Blancing diversion control and medical necessity: The case of prescription drugs with abuse potential. Substance Abuse Misuse 36 (2001) 1275-1296
91. Hall A.J., Logan J.E., Toblin R.L., Kaplan J.A., Kraner J.C., Bixler D., et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300 (2008) 2613-2620
92. Fudala P.J., and Johnson R.E. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 83 Suppl 1 (2006) S40-S47
93. Butler S.F., Budman S.H., Licari A., Cassidy T.A., Lioy K., Dickinson J., et al. National addictions vigilance intervention and prevention program (NAVIPPRO-TM: A real-time, product-specific. public health surveillance system for monitoring prescription drug abuse. Pharmacol Drug Safety (2008) [In press]
94. Paulozzi L.J. Trends in unintentional drug overdose deaths. Testimony before Senate Judiciary Committee on Crime and Drugs. March 12, 2008. http://www.hhs.gov/asl/testify/2008/03/t20080312b.html Accessed January 21, 2010
95. TheraQuest Biosciences. Our product candidates. http://www.theraquestinc.com/pipeline/products.htm2006 Accessed February 20, 2009
96. TheraQuest Biosciences. Ultram-ER extended-release tablets. 2008. http://www.theraquest.com Accessed February 20, 2009
97. TheraQuest Biosciences. 2009. http://www.theraquest.com Accessed February 20, 2009
98. TheraQuest Biosciences. TheraQuest's IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA. November 13, 2008. http://www.theraquestinc.com/news/pressrelease/pr_08_11_13.htm Accessed February 23, 2009
99. Lavine G. Abuse deterrence focus of upcoming opioid formulations. Am J Health Syst Pharm 65 (2008) 381, 385
100. Gershell L., and Goater J.J. Making gains in pain. Nat Rev Drug Discov 5 (2006) 889-890
101. Webster L.R. PTI-821: Sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs 16 (2007) 359-366
102. ™ cleared for US Clinical trials. Pain Therapeutics, Inc. September 2, 2004. Available online at: http://investor.paintrials.com/releasedetail.cfm?ReleaseID=297384. Accessed September 23, 2009.
103. IntelliPharmaCeutics announces successful completion of a pilot clinical trial for its abuse and alcohol resistant sustained release oxycodone. IntelliPharmaCeutics Ltd. March 27, 2008. Available online at: http://www.intellipharmaceutics.com/contact/news_2008_march_27.htm. Accessed August 7, 2009.
104. Akela Pharmaceuticals, Inc. Akela Pharmaceuticals initiates its first abuse deterrent opioid phase I clinical trial. March 6, 2008. http://www.akelapharma.com/modules.php?op=modload&name=News&file =article&sid=67 Accessed September 23, 2009
105. Collegium Pharmaceutical Inc. Collegium Pharmaceutical Inc. announces FDA acceptance of IND for its abuse deterrent sustained release opioid product. July 12, 2007. http://www.collegiumpharma.com/news/20070712.html Accessed September 24, 2009
106. Collegium Pharmaceutical Inc. Collegium Pharmaceutical Inc. announces submission of a request for special protocol assessment to FDA for pivotal trial for tamper resistant, extended release opioid (COL-003). [press release]. June 10, 2009. http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_v iew&newsId=20090610005046&newsLang=en
107. Sathyan G., Sivakumar K., and Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 24 (2008) 297-305
108. Sathyan G., Xu E., Thipphawong J., and Gupta S.K. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol 7 (2007) 3-8
109. Webster L.R., Bath B., and Medve R.A. Opioid formulations in development designed to curtail abuse: Who is the target?. Expert Opin Investig Drugs 18 (2009) 255-263
110. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 10 (2009) S124-S133
111. Neuromed Pharmaceuticals, Inc. Neuromed announces Exalgo (hydromorphone HCl) extended-release tablet [press release]. PharmaLive.com news archive. March 23, 2009.
112. CombintoRx, Incorporated and Neuromed Pharmaceuticals Inc. FDA extends NDA review for Exalgo extended-release tablets [press release]. PharmaLive.com news archive. November 20, 2009.
113. Innovators in pain management. Egalet a/s. http://www.egalet.com Accessed January 11, 2010
114. Egalet a/s. Effects of a single dose of Egalet®. morphine combined with a single dose of alcohol in healthy moderate drinkers. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[January 11, 2010]. Available online at: http://clinicaltrials.gov/ct2/show/NCT00802308 NLM Identifier: NCT00802308.
115. Andersen C., and Jespersen L. Egalet® morphine, a once-a-day abuse resistant opioid analgesic: A.double-blind, randomized, cross-over efficacy study in cancer patients. J Pain 10 (2009) S36
116. Egalet a/s. Single dose pharmacokinetics of Egalet® oxycodone. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[January 11, 2010]. Available online at: http://clinicaltrials.gov/ct2/show/NCT00801788 NLM Identifier: NCT00801788.
117. Egalet a/s. Single dose pharmacokinetics of Egalet® hydrocodone. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[January 11, 2010]. Available online at: http://clinicaltrials.gov/ct2/show/NCT00802087 NLM Identifier: NCT00802087.
118. Embeda [package insert]. Bristol, TN: King Pharmaceuticals®, Inc.; June, 2009.
119. Purdue Pharma L.P. Meeting background material. Joint meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) (May 5, 2008) 155-159